Experimental drug offers hope for patients Who've run out of options

NCT ID NCT07306559

Summary

This study is testing a new immunotherapy drug called BI 3820768 for the first time in people. It's for adults with advanced germ cell, endometrial, or ovarian cancer that has returned or stopped responding to standard treatments. The main goal is to find a safe and tolerable dose that might help shrink tumors by boosting the body's immune system to fight cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED RELAPSED OR REFRACTORY GERM CELL TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cliniques Universitaires Saint-Luc

    NOT_YET_RECRUITING

    Brussels, 1200, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Clínica Universidad de Navarra - Madrid

    NOT_YET_RECRUITING

    Madrid, 28027, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitari Vall d'Hebron

    NOT_YET_RECRUITING

    Barcelona, 08035, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • INS Paoli-Calmettes

    NOT_YET_RECRUITING

    Marseille, 13009, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Indiana University

    NOT_YET_RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Gustave Roussy

    NOT_YET_RECRUITING

    Villejuif, 94800, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Japanese Foundation for Cancer Research

    NOT_YET_RECRUITING

    Tokyo, Koto-ku, 135-8550, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Klinikum der Universität München AÖR

    NOT_YET_RECRUITING

    München, 81377, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Cancer Center Hospital East

    NOT_YET_RECRUITING

    Chiba, Kashiwa, 277-8577, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The University of Texas MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UZ Leuven

    SUSPENDED

    Leuven, 3000, Belgium

  • Universitätsklinikum Würzburg AÖR

    NOT_YET_RECRUITING

    Würzburg, 97078, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Valkyrie Clinical Trials

    RECRUITING

    Los Angeles, California, 90067, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.